OSSIO has closed an initial $40 million senior credit facility, with an additional $10 million available to support future growth, according to Horizon Technology Finance Corporation and Monroe Capital. The financing is designed to provide growth capital as OSSIO expands its orthopedic fixation technology globally.
Founded in 2014, OSSIO is focused on developing a potential alternative to metal implants in the global orthopedic fixation market through its OSSIOfiber Intelligent Bone Regeneration Technology. The company conducts product development and manufacturing in Caesarea, Israel, and maintains commercial operations in Palmetto, Florida.
Horizon and Monroe said the facility reflects their focus on providing secured lending solutions to venture and private equity-backed companies across technology, life sciences, healthcare, and sustainability. The firms positioned the OSSIO transaction as part of their broader activity in technology finance and healthcare innovation, including within Israel’s life sciences ecosystem.
KEY QUOTES
“We are thrilled to partner with Horizon Technology Finance and Monroe Capital on this growth capital investment. We look forward to executing on our strategy to expand our orthopedic fixation technology globally. This partnership combines deep healthcare technology expertise with growth capital. Financing from the Horizon and Monroe platform provides the resources needed to accelerate expansion while preserving the company’s mission of transforming the orthopedic experience for patients.”
Brian Verrier, Chief Executive Officer, OSSIO
“We are excited to partner with Brian and the OSSIO team as they broaden their global impact in orthopedic medical technology. This investment reflects Horizon’s commitment to supporting innovative, venture growth companies through strategic financing. OSSIO marks another Horizon investment within the Israeli technology ecosystem.”
Paul Seitz, Chief Investment Officer, Horizon Technology Finance
“Monroe continues to see exceptional innovation emerging from the Israeli life sciences sector, and OSSIO stands out as a leading force in orthopedic and regenerative technology. Its disruptive, metal-free bone regeneration solutions align directly with our technology finance vertical, and we are proud to support Brian and his team as they globally scale OSSIO’s impact.”
Mark Solovy, Managing Director And Co-Head, Technology Finance Group, Monroe Capital
